IN THE CLAIMS

The following provides the status of the claims pending in the application.

1. (Previously presented) A method of diagnosing sepsis in a human subject, comprising:
determining a concentration of at least one analyte in a test sample from said human subject;
comparing the concentration of each said analyte(s) to a corresponding reference concentration selected to indicate the presence or absence of sepsis, wherein said reference concentration is determined using one or more control samples obtained from one or more human subjects not suffering from sepsis,
provided that at least one of said analyte(s) is myeloid progenitor inhibitory factor-1 ("MPIF-1"), wherein an elevated concentration of MPIF-1 in the test sample relative to the reference concentration is indicative of the presence of sepsis in the human; and
diagnosing sepsis in the human subject using the result(s) of said comparing step.

2. (Original) The method of claim 1 wherein said samples comprise blood.

3. (Original) The method of claim 1 wherein said samples comprise serum.

4. (Original) The method of claim 1 wherein said samples comprise plasma.

5. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is interleukin 1 receptor antagonist ("IL-1 Ra").

6. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is monocyte chemotactic protein-1 ("MCP-1").

7. Cancelled

8. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is tumor necrosis factor receptor-1 ("TNF-R1").

9. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is monokine induced by interferon gamma ("MIG").

10. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is B-lymphocyte chemoattractant ("BLC").

11. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is herpes virus entry factor ("HVEM").

12. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is interleukin-15 ("IL-15").

13. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is monocyte chemotactic protein-2 ("MCP-2").

14. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is macrophage colony stimulating factor ("M-CSF").

15. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is monocyte chemotactic protein-3 beta ("MIP-3β").

16. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is matrix metalloproteinase-9 ("MMP-9").

17. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is pulmonary and activation-regulated chemokine ("PARC").

18. (Previously presented) The method of claim 1 wherein further provided that at least one analyte is interleukin 1 receptor antagonist ("ST-2").

19. (Previously presented) The method of claim 1 wherein sepsis is diagnosed if at least two of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

20. (Previously presented) The method of claim 1 wherein sepsis is diagnosed if at least three of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

21. (Previously presented) The method of claim 1 wherein sepsis is diagnosed if at least four of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

22. (Previously presented) The method of claim 1 wherein sepsis is diagnosed if at least five of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

23. (Previously presented) The method of claim 1 wherein sepsis is diagnosed if at least six of said analytes in said test sample are elevated relative to the corresponding reference concentrations.

24-95. Cancelled

96. (Previously presented) The method of claim 1, further provided that at least one analyte is selected from the group consisting of epidermal growth factor ("EGF"), epithelial cell-derived

neutrophil activating peptide ("ENA-78"), eotaxin ("EOT"), growth-related oncogene beta ("Gro-β"), interleukin-1 beta ("IL-1β"), Leptin, macrophage migration inhibitory factor ("MIF"), macrophage inflammatory protein-1 alpha ("MIP-1α"), oncostatin M ("OSM"), Protein C, P-Selectin, and hemofiltrate CC chemokine 4 ("HCC4").

97. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is EGF.

98. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is ENA-78.

99. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is EOT.

100. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is Gro-β.

101. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is IL-1β.

102. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is Leptin.

103. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is MIF.

104. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is MIP-1α.

105. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is OSM.

106. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is Protein C.

107. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is P-Selectin.

108. (Previously presented) The method of claim 96 wherein further provided that at least one analyte is HCC4.